Supreme Court Stays Fifth Circuit Order on FDA Mifepristone Rules Pending Review
The stay preserves the status quo for tele-abortion prescriptions while the Court's eventual ruling could set binding federal standards for how the FDA regulates medication abortion access nationwide.
The U.S. Supreme Court on May 14, 2026, issued a stay of the Fifth Circuit Court of Appeals' order that had challenged the Food and Drug Administration's current regulatory framework governing mifepristone, according to reporting by the Washington Examiner. The stay keeps in place the FDA's existing rules permitting tele-health prescriptions and mail-order distribution of the abortion pill while litigation in Louisiana v. FDA continues through the federal court system.
The case centers on whether the FDA followed proper administrative procedure when it expanded access to mifepristone — a two-drug regimen approved by the FDA in 2000 — through regulatory actions taken in 2016 and 2021 that removed in-person dispensing requirements and extended the permissible gestational window for use. Plaintiffs in Louisiana v. FDA argue those rule changes exceeded the agency's statutory authority under the Federal Food, Drug, and Cosmetic Act. The FDA and the Department of Justice have maintained the agency acted within its established regulatory discretion.
The Supreme Court's decision to issue the stay signals it determined that allowing the Fifth Circuit's order to take immediate effect could cause irreparable harm before the justices have the opportunity to fully consider the underlying legal questions. A stay at this stage does not constitute a ruling on the merits of either party's arguments. The Court has not yet announced whether it will grant certiorari to hear the case directly, which would be confirmed through a formal order listed on the Court's public docket at supremecourt.gov.
The litigation arrives nearly four years after the Court's June 2022 ruling in Dobbs v. Jackson Women's Health Organization (597 U.S. 215), which overturned Roe v. Wade and Planned Parenthood v. Casey, returning abortion regulatory authority to individual states. Because mifepristone is dispensed under a federal regulatory framework — the FDA's Risk Evaluation and Mitigation Strategy, or REMS, program — the outcome of Louisiana v. FDA would have nationwide implications that operate independently of individual state abortion statutes.
What remains unknown is the timeline for the Court's final resolution of the case and whether it will accept the matter for full briefing and oral argument. The Court's conference schedule and any certiorari grant or denial would be reflected on the official Supreme Court docket. The precise legal standard the Court would apply to evaluate FDA's 2016 and 2021 regulatory changes — particularly in light of its 2024 decision in Loper Bright Enterprises v. Raimondo, which curtailed judicial deference to agency interpretations — has not yet been established in this case and would constitute a central question in any merits briefing.